Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255684 · ClinicalTrials.gov registry record · NA
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
A NA study, sponsored by University of Rochester.
- Terminated
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT00255684 is a NA study that was terminated before completion, run by University of Rochester. The registered enrollment target is 16 participants.
The verdict
NCT00255684, a NA study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This clinical trial is studying how well giving fludarabine and cyclophosphamide together with total-body irradiation followed by cyclosporine and mycophenolate mofetil works in treating patients who are undergoing a donor umbilical cord blood transplant for hematologic cancer.
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- DRUG cyclosporine
- DRUG mycophenolate mofetil
- BIOLOGICAL graft-versus-tumor induction therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2003-12 |
| Est. Completion | 2016-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255684
The ClinicalTrials.gov registry entry for NCT00255684 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00255684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00255684 about?
NCT00255684 is a clinical study titled "Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer". RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated st...
What is the current status of trial NCT00255684?
This trial is currently terminated. It is a NA study. The enrollment target is 16 participants. The study started on 2003-12. Estimated completion is 2016-06.
What interventions are being tested in trial NCT00255684?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), cyclosporine (DRUG), mycophenolate mofetil (DRUG), graft-versus-tumor induction therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00255684?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.